TLE1 as a key regulator of osimertinib resistance and EMT in lung adenocarcinoma: implications for prognosis and immunotherapy response

Na Chen, Tianlin Wang, Yi Li, Ruixia Zhang, Xiduan Wei, Zhenglu Wang · 2026

Read TLE1 as a key regulator of osimertinib resistance and EMT in lung adenocarcinoma: implications for prognosis and immunotherapy response by Na Chen, Tianlin Wang, Yi Li, Ruixia Zhang, Xiduan Wei, Zhenglu Wang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13425785.txt.

Description

Na Chen and colleagues hunt for a marker of resistance to osimertinib, a drug used for lung adenocarcinoma, a common form of non-small cell lung cancer. Long-term treatment often fails as tumours learn to resist drugs that block the epidermal growth factor receiver.

Gene data from large public banks were screened against a set of genes tied to histone marks, and TLE1 stood out. Survival checks, pathway scoring, and immune-cell estimates were run, and lab tests that silenced TLE1 probed its role in resistance. Clinicians get a named candidate for predicting who may stop responding and who may gain from immune treatment.

Catalog record

CREATORNa Chen, Tianlin Wang, Yi Li, Ruixia Zhang, Xiduan Wei, Zhenglu Wang
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE47 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13425785

Browse the full library · About the Tower of Babel